New Trial for Lung Cancer Opens in Australia
The Australasian Lung Cancer Trials Group (ALTG), working with the National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC) and research groups in other countries has launched the BR.31 trial in Australia. BR.31 is a clinical research study that is testing MEDI4736, a new type of drug treatment for non-small cell lung cancer (NSCLC) that has been completely removed by surgery. The purpose of this study is to find out whether it is better to receive MEDI4736 or no further treatment after surgery (and possibly chemotherapy) for lung cancer. Laboratory tests show that MEDI4736 works by preventing one of the ways that cancer may avoid detection by the immune system (the interaction between PD1 and PDL1). By reactivating the immune response MEDI4736 treatment may help to slow down the growth of lung cancer or cause cancer cells to die. Visit Lung Foundation Australia’s ALTG website www.altg.com.au/altg-14001-br31 for more information about BR.31 and other ALTG studies.